keyword
MENU ▼
Read by QxMD icon Read
search

lercanidipine

keyword
https://www.readbyqxmd.com/read/27895487/combination-therapy-with-lercanidipine-and-enalapril-in-the-management-of-the-hypertensive-patient-an-update-of-the-evidence
#1
REVIEW
Christina Antza, Stella Stabouli, Vasilios Kotsis
Hypertension is an important risk factor for premature death as it increases the probability of stroke, myocardial infarction, and heart failure. Antihypertensive drugs can decrease cardiovascular (CV) morbidity and mortality. The majority of hypertensive patients need more than one antihypertensive agent to attain blood pressure (BP) targets. Monotherapy can effectively reduce BP only in 20%-40% of patients. Multiple mechanisms including increased peripheral vascular resistance, increased cardiac work, and hypervolemia are involved in the pathogenesis of hypertension...
2016: Vascular Health and Risk Management
https://www.readbyqxmd.com/read/27794423/neuroprotective-effect-of-lercanidipine-in-middle-cerebral-artery-occlusion-model-of-stroke-in-rats
#2
Sangeetha Gupta, Uma Sharma, Naranamangalam R Jagannathan, Yogendra Kumar Gupta
Oxidative stress, inflammation and apoptotic neuronal cell death are cardinal mechanisms involved in the cascade of acute ischemic stroke. Lercanidipine apart from calcium channel blocking activity possesses anti-oxidant, anti-inflammatory and anti-apoptotic properties. In the present study, we investigated neuroprotective efficacy and therapeutic time window of lercanidipine in a 2h middle cerebral artery occlusion (MCAo) model in male Wistar rats. The study design included: acute (pre-treatment and post-treatment) and sub-acute studies...
October 26, 2016: Experimental Neurology
https://www.readbyqxmd.com/read/27779461/differential-effects-of-lercanidipine-enalapril-versus-amlodipine-enalapril-and-hydrochlorothiazide-enalapril-on-target-organ-damage-and-sympathetic-activation-in-non-obese-essential-hypertensive-subjects
#3
K Tsioufis, Costas Tsioufis, Kyriakos Dimitriadis, Emmanouil Mantzouranis, Ilianna Mani, Dimitrios Tousoulis
OBJECTIVE: The aim of the present study was to compare the effects of the combination of lercanidipine/enalapril versus amlodipine/enalapril and hydrochlorothiazide/enalapril on blood pressure, target organ damage and sympathetic activation in patients with grade 2 essential hypertension. RESEARCH DESIGN AND METHODS: This was a 3 month, randomized, blinded-endpoint study in essential hypertensive patients. MAIN OUTCOME MEASURES: Office and ambulatory blood pressure, arterial stiffness, urinary albumin to creatinine ratio, renal arterial resistive index, and muscle sympathetic nerve activity were evaluated at baseline, after a 2 week run-in placebo period, at 1 month and at 3 months...
October 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27779460/lercanidipine-valuable-effect-on-urine-protein-losses-the-red-level-study
#4
Nicolas Roberto Robles, Carlos Calvo, Javier Sobrino, Eugenia Espinel, Rafael Esteban, Lourdes Mateos, Juan F Macias
OBJECTIVE: The RED LEVEL study (REnal Disease: LErcanidipine Valuable Effect on urine protein Losses) directly compares, in an explorative fashion, the effects of lercanidipine + enalapril and amlodipine + enalapril combinations on renal parameters in hypertensive subjects. RESEARCH DESIGN AND METHODS: This was a 1 year, prospective, multi-center, randomized, open-label, blinded-endpoint (PROBE) study in hypertensive patients with albuminuria. MAIN OUTCOME MEASURES: Renal function (albuminuria, serum creatinine, creatinine clearance, estimated glomerular filtration rate and proteinuria); blood pressure...
October 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27779459/vascular-effects-of-the-lercanidipine-enalapril-combination-clinical-relevance
#5
Gianfranco Parati
Hypertension is associated with alterations in the vascular structure, which in turn enhance the risk of cardiovascular events. Notably, anti-hypertensive treatment may prevent or regress the changes of arterial wall structures. Lercanidipine is a third-generation CCB with peculiar pharmaceutical properties. Enalapril is an effective drug acting on the renin-angiotensin-aldosterone axis. This commentary discusses the vascular effects of the lercanidipine/enalapril combination, and comments on their potential clinical relevance...
October 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27779458/dose-response-effect-of-the-lercanidipine-enalapril-combination-a-pooled-analysis
#6
Damiano Rizzoni
OBJECTIVE: The dose-effect relationship of fixed-dose combinations of anti-hypertensive drugs has been only poorly explored. This pooled analysis investigates the dose-response relationship of fixed-dose lercanidipine + enalapril in patients with mild-to-moderate hypertension. RESEARCH DESIGN AND METHODS: This was an individual patient data analysis of four randomized studies (n = 2340). MAIN OUTCOME MEASURES: The primary efficacy variable was the change from baseline in sitting diastolic blood pressure (SDBP)...
October 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27779457/fixed-dose-lercanidipine-and-enalapril-in-field-practice-a-meta-analysis
#7
Damiano Rizzoni
OBJECTIVE: This meta-analysis evaluates the efficacy and safety of lercanidipine/enalapril fixed-dose combination in patients with mild to moderate essential hypertension. METHODS: Four observational studies on patients with sitting diastolic blood pressure (SDBP) between 95 and 109 mmHg, treated with lercanidipine/enalapril fixed-dose combination, were analyzed. The Random-Effect Model was used to limit heterogeneity across the studies. Weights were applied to determine the influence of each study on the combined results...
October 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27779456/lercanidipine-effect-on-circulating-cd34-progenitor-cells-in-elderly-patients-a-randomized-study
#8
Shen Peixiao, Fang Ningyuan, Wang Haiya
OBJECTIVE: This randomized study evaluates the effects of lercanidipine - as well as its antihypertensive efficacy - on the number of circulating endothelial progenitor cells (EPCs) in elderly patients with hypertension. RESEARCH DESIGN AND METHODS: In total, 61 patients with hypertension were randomly assigned to lercanidipine 10 mg/day or to other antihypertensive treatments (control group). MAIN OUTCOME MEASURES: Cytometry analysis was conducted at baseline, at 12 weeks and at 24 weeks...
October 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27779454/effects-of-lercanidipine-hydrochloride-versus-felodipine-sustained-release-on-day-to-day-home-blood-pressure-variability
#9
Mengdan Xu, Ying Wu, Hao Wang, Xin Xu, Shuiping Zhao, Mei Zhang, Huigen- Jin, Jinchuan Yan, Bangning Wang, Jianbin Gong, Xiang Lu, Jianqiang Peng, Qiuyan Dai
OBJECTIVE: The objective of this study was to compare the effectiveness of lercanidipine with felodipine in patients with mild-to-moderate hypertension on day-to-day home blood pressure variability. METHODS: This is a sub-study of a multicenter, randomized, open-label, parallel group and active controlled clinical trial. Hypertensive patients aged 18-75 (i.e. diastolic blood pressure ≥90 mmHg and <110 mmHg; systolic blood pressure ≥140 mmHg and <180 mmHg) and 24 h mean BP >130/80 mmHg) were eligible for this study...
October 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27779453/the-fixed-dose-combination-of-lercanidipine-and-enalapril-more-than-mere-blood-pressure-reduction
#10
Enrico Agabiti Rosei
No abstract text is available yet for this article.
October 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27544752/a-novel-nanoproliposomes-of-lercanidipine-development-in-vitro-and-preclinical-studies-to-support-its-effectiveness-in-hypertension-therapy
#11
Praful Balavant Deshpande, Aravind Kumar Gurram, Amruta Deshpande, Gopal Venkatesh Shavi, Prashant Musmade, Karthik Arumugam, Ranjith Kumar Averineni, Srinivas Mutalik, Meka Sreenivasa Reddy, Nayanabhirama Udupa
AIM: The aim of the present study was to develop nanoproliposomes of lercanidipine, in order to overcome its poor biopharmaceutical properties and to improve its therapeutic efficacy in treating hypertension. MAIN METHODS: The nanoproliposomes were prepared using a modified thin-film hydration method, and the formula was optimized by varying the ratio of lipids and the types of cryoprotectants. This optimized formulation was characterized in terms of its particle size, solid-state, drug release, in-situ absorption, in-vivo pharmacokinetics, and in-vivo anti-hypertensive activity in DOCA-salt induced hypertensive rats...
October 1, 2016: Life Sciences
https://www.readbyqxmd.com/read/27508596/-op-lb03-07-effects-of-lercanidipine-enalapril-compared-with-amlodipine-enalapril-and-hydrochlorothiazide-enalapril-on-target-organ-damage-and-sympathetic-activity-in-hypertension
#12
C Tsioufis, A Kasiakogias, K Dimitriadis, T Kalos, I Liatakis, D Konstantinidis, E Andrikou, L Nikolopoulou, E Vlachos, K Kyriazopoulos, D Tousoulis
OBJECTIVE: The aim of the study is to compare in essential hypertensives the effects of lercanidipine/enalapril versus amlodipine/enalapril and enalapril/hydrochlorothiazide on various target organ damage end-points as well as on sympathetic nervous system activation during a follow-up period of 3 months. DESIGN AND METHOD: We studied 56 untreated patients with essential hypertension stage II [age: 56 ± 10 years, 30 males, office blood pressure (BP): 148/92 ± 14/11 mmHg] who were randomized to lercanidipine 10 mg/enalapril 20 mg (once daily) or amlodipine 5 mg/enalapril 20 mg (once daily) or enalapril 20 mg/hydrochlorothiazide 12...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27412800/dihydropyridine-calcium-channel-blockers-and-renal-disease
#13
Nicolás R Robles, Francesco Fici, Guido Grassi
Although blood pressure control is considered the main mechanism for preventing the progression of chronic kidney disease (CKD), angiotensin-converting enzyme inhibitors and angiotensin receptors blockers have an additional organ-protective role. The effects of calcium channel blockers (CCBs) in renal disease are not so clearly defined. CCBs have pleiotropic effects that might contribute to protection of the kidney, such as attenuating the mesangial entrapment of macromolecules, countervailing the mitogenic effect of platelet-derived growth factors and platelet-activating factors and suppressing mesangial cell proliferation...
July 14, 2016: Hypertension Research: Official Journal of the Japanese Society of Hypertension
https://www.readbyqxmd.com/read/27405507/simultaneous-determination-of-a-fixed-dose-combination-of-lercanidipine-and-valsartan-in-human-plasma-by-lc-ms-ms-application-to-a-pharmacokinetic-study
#14
Eboka Majolene B Sabi-Mouka, Janvier Engelbert Agbokponto, Run Zhang, Qian Li, Li Ding
A simple, sensitive and reproducible liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-MS-MS) method was developed and validated for the first time for simultaneous quantification of lercanidipine and valsartan in human plasma. The analytes were extracted by simple protein precipitation with acetonitrile and separated on a Hanbon Hedera ODS-2 C18 (150 mm× 2.1 mm, 5 μm) column. The mobile phase was composed of a mixture (53:47, v/v) of acetonitrile and 10 mmol/L ammonium acetate containing 0...
July 12, 2016: Journal of Chromatographic Science
https://www.readbyqxmd.com/read/27392121/amlodipine-treatment-of-hypertension-associates-with-a-decreased-dementia-risk
#15
Leonid Feldman, Shlomo Vinker, Shai Efrati, Ilia Beberashvili, Oleg Gorelik, Walter Wasser, Michal Shani
Hypertension has been shown to be a risk factor for development of dementia. However, medical treatment of hypertension failed to reduce consistently the risk of dementia. Experimental study pointed to the possibility of difference between different calcium channel blockers (CCB) in their neuro-protective effect. The aim of our study was to evaluate the risk of dementia during treatment of hypertension with different CCBs. This is a retrospective cohort study based on electronic database of a large public health care organization...
2016: Clinical and Experimental Hypertension: CHE
https://www.readbyqxmd.com/read/27232153/a-rapid-and-sensitive-lc-ms-ms-method-for-determination-of-lercanidipine-in-human-plasma-and-its-application-in-a-bioequivalence-study-in-chinese-healthy-volunteers
#16
Xiaobing Li, Fuguo Shi, Xiaojing He, Lingyan Jian, Li Ding
A rapid and highly sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method has been developed and validated for the determination of lercanidipine (LER) in human plasma. The plasma sample was deproteinized with methanol after addition of diazepam (internal standard, IS) and separated on a 38°C Hedera ODS-2 analytical column with a mobile phase of methanol and 5mM ammonium acetate buffer solution containing 0.1% formic acid at an isocratic flow rate of 400μL/min. The detection was performed on an API 4000 tandem mass spectrometer coupled with electrospray ionization (ESI) source in positive ESI mode...
September 5, 2016: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/27195656/effect-of-antihypertensive-treatment-with-lercanidipine-on-endothelial-progenitor-cells-and-inflammation-in-patients-with-mild-to-moderate-essential-hypertension
#17
Carolina De Ciuceis, Claudia Rossini, Angela Tincani, Paolo Airò, Mirco Scarsi, Claudia Agabiti-Rosei, Giuseppina Ruggeri, Luigi Caimi, Doris Ricotta, Enrico Agabiti-Rosei, Damiano Rizzoni
BACKGROUND: It has been demonstrated that circulating endothelial progenitor cells (EPCs) number reflects the endogenous vascular repair ability, with the EPCs pool declining in presence of cardiovascular risk factors. Several drugs, including dihydropyridine calcium channel blockers, have been reported to elicit antioxidant and anti-inflammatory properties, as well as to improve vascular remodeling and dysfunction. However, no data are available about the effects of lercanidipine on EPCs...
May 19, 2016: Blood Pressure
https://www.readbyqxmd.com/read/27175094/lercanidipine-enalapril-combination-in-the-management-of-obesity-related-hypertension
#18
REVIEW
Guido Grassi
Obesity-related hypertension represents a condition frequently observed in current clinical practice characterized by a complex pathophysiological background and a very high cardiovascular risk profile, particularly in severely obese individuals. This explains, on the one hand, the difficulty in reducing elevated blood pressure values in this pathological state and, on the other, the need to achieve this goal in a relatively short-time period to prevent the occurrence of fatal and nonfatal cardiovascular events...
2016: Integrated Blood Pressure Control
https://www.readbyqxmd.com/read/27068332/barnidipine-compared-to-lercanidipine-in-addition-to-losartan-on-endothelial-damage-and-oxidative-stress-parameters-in-patients-with-hypertension-and-type-2-diabetes-mellitus
#19
Giuseppe Derosa, Amedeo Mugellini, Rosa Maria Pesce, Angela D'Angelo, Pamela Maffioli
BACKGROUND: Essential hypertension has been extensively reported to cause endothelial dysfunction. The aim of this study was to evaluate the effects of barnidipine or lercanidipine, in addition to losartan, on some parameters indicative of endothelial damage and oxidative stress in hypertensive, type 2 diabetic patients. METHODS: One hundred and fifty one patients were randomised to barnidipine, 20 mg/day, or lercanidipine, 20 mg/day, both in addition to losartan, 100 mg/day, for 6 months...
2016: BMC Cardiovascular Disorders
https://www.readbyqxmd.com/read/27063592/development-of-fast-dissolving-oral-films-containing-lercanidipine-hcl-nanoparticles-in-semicrystalline-polymeric-matrix-for-enhanced-dissolution-and-ex-vivo-permeation
#20
Ankita D Chonkar, J Venkat Rao, Renuka S Managuli, Srinivas Mutalik, Swapnil Dengale, Prateek Jain, N Udupa
Lercanidipine is a vasoselective dihydropyridine calcium antagonist, mainly used for the treatment of hypertension and angina pectoris. However, it suffers from food dependent absorption, poor solubility, low permeability and considerable first pass metabolism, resulting in highly variable and low bioavailability of 10%. Nanoparticles of lercanidipine were incorporated in fast dissolving oral films (FDO) via preparation of nanosuspension by evaporative antisolvent precipitation method. Prepared nanosuspensions were incorporated in FDO without lyophilizing or spray drying...
June 2016: European Journal of Pharmaceutics and Biopharmaceutics
keyword
keyword
54850
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"